Early combination lipid-lowering therapy with high-intensity statins and ezetimibe protects against later cardiovascular ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

An osteoanabolic agent should be the first choice treatment for patients at high or imminent risk for fracture, but once ...

Ever wondered why we call it a “heart attack” but doctors say “myocardial infarction”? In this video, I explore the fascinating (and sometimes hilarious) origins of medical terms, from Greek and Latin ...

The National Psoriasis Foundation will host its annual Commit to Cure gala on June 18, the organization’s largest fundraiser ...

Percutaneous coronary intervention to seal non–flow-limiting vulnerable plaques is associated with a lower incidence of cardiac outcomes, regardless of the patient’s diabetes status, a study finds.

Silent heart attacks often lack classic symptoms like intense chest pain. Subtle signs like unexplained fatigue, shortness of ...

Discontinuing Beta-blocker therapy after an uncomplicated myocardial infarction (MI) was found to cause a persistent rise in ...

The AHA’s PREVENT equations, compared with pooled cohort equations, can better predict 10-year ASCVD risk among US adults.

This study presents compelling evidence that the denitrosylase SCoR2 regulates cardioprotective metabolic reprogramming in the heart following ischemia/reperfusion injury. The findings are supported ...

Akebia Therapeutics had a strong US launch of Vafseo and Q1 revenues signal robust demand, but near-term profitability ...